ReviewCurrent allergy and asthma reports2009
The pharmacogenetics of asthma treatment.
Review in Current allergy and asthma reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Steroid Pathway Genes and Neonatal Respiratory Distress After Betamethasone Use in Anticipated Preterm Birth.Reproductive sciences (Thousand Oaks, Calif.) · 2016Article
- Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and CTNNA3 are associated with disease severity and treatment response in childhood asthma.Immunogenetics · 2014Article
- Pharmacogenetics and individualizing drug treatment during pregnancy.Pharmacogenomics · 2014Review
- The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration.American journal of obstetrics and gynecology · 2013Article
- Integrative systems biology approaches in asthma pharmacogenomics.Pharmacogenomics · 2012Review
- The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.American journal of obstetrics and gynecology · 2012Article
- TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus.PloS one · 2010Article
- Development of a Pharmacogenetic Predictive Test in asthma: proof of concept.Pharmacogenetics and genomics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The treatment response to each of the three major classes of asthma medications-beta agonists, leukotriene modifiers, and inhaled corticosteroids-demonstrates substantial interindividual variability. Evidence indicates that this variability is mediated, at least in part, by genetic factors. Pharmacogenetics is the study of the role of heritable factors in the response to pharmacologic therapy. The goal of pharmacogenetics is "predictive medicine," whereby a genetic profile, combined with clinical characteristics, can be used to predict response to medications a priori, allowing for maximal therapeutic response while minimizing side effects. In this review, we discuss the rationale behind conducting asthma pharmacogenetics studies, provide an overview of asthma pharmacogenetic phenotypes, and detail the most important results of asthma pharmacogenetics studies conducted to date. Although no specific predictive tests have been developed thus far, the existing studies serve as strong proof of concept of the applicability of pharmacogenetics in the future management of asthma.
Indexed as
Identifiers
19063819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.